Preparing healthcare companies for success
in the value-based economy

RE Presents: Solving the Medicare Co-Pay Dilemma

Event Details


Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.

more >


Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.

more >

Our Solutions

News and Events

Real Endpoints Strengthens and Broadens Access Capabilities and Reach with the Hiring of Key Executive

by Real Endpoints

Real Endpoints (RE), a leading boutique life science consultancy focused on market access, today announced it has hired Robert O’Brien as Vice President, Specialty to further expand its abilities to gain access and coverage for its clients’ medical innovations.

November 10, 2020

read full press release >

High Priced Drugs for Rare Disease: Leading US Payers Discuss Cost Concerns, Value-Based Contracts and ICER

by Cathy Kelly

Expert perspectives on reimbursement for high-cost therapies, both chronic and curative, were discussd at the recent Biotechnology Innovation Organization virtual international convention. The panel discussion, moderated by Real Endpoints CEO Jeff Berkowitz, focused on pharmacy benefit manager and payer concerns with affordability, the role of patient advocacy, value-based purchasing, and ICER value assessments

June 14, 2020

Pink Sheet

read full article >

Rare Disease Therapies are No Longer Rare: Can the US Healthcare Reimbursement System Handle Chronic Treatments for Orphan Diseases

Moderator: Jeffrey Berkowitz, CEO and Director

Real Endpoints

Real Endpoints is excited to be moderating this important panel on reimbursement of chronic rare and orphan disease therapies at the upcoming BIO International Digital Convention

June 8, 2020 -
June 12, 2020

event >

Recent Insights

view archive >

June 30, 2020

Opportunity Offered by a Good Crisis: COVID-19 IMPACT ON INNOVATIVE PRICING MODELS

An interview with Roger Longman, Cofounder and Chairman of Real Endpoints LLC in which he discusses innovative and value-based contracting models currently in use and reflects on the downstream effects of innovative pricing on patients and their out-of-pocket costs.

read full interview >

April 20, 2020

Drug Coverage in the Pandemic: US Payers Shift Focus From Costs To Access, For Now

US payers are concentrating on ensuring access to health care during the COVID-19 pandemic, which has led them to relax, postpone or waive some formulary and coverage policies to avoid disruptions in patient access to prescription drugs.

read full insights article >